← Insulin × cardiovascular events

TrialThe American journal of medicine2018

Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease.

Jannik Langtved Pallisgaard et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2,319 people · 2018

Range includes no effect

No clear effect on cardiovascular events

−9%−40% to +38%

Bigger than 1 in 10 for cardiovascular events

As reported

HR 0.91, 95% CI 0.60–1.38

What moved togetherboth groups pooled, not the treatment’s effect

Correlation · may be no link

No clear link with pharmacokinetics & dosing

−20%−67% to +94%

Bigger than 4 in 10 on the map

As reported

HR 0.80, 95% CI 0.33–1.94

Two numbers in the abstract

the abstract, start to end

… with an adjusted HR of 0.80 (95% CI, 0.33-1.94, P = .62).

… provision with a hazard ratio (HR) of 0.91 (95% confidence interval [CI], …

← favours treatmentfavours comparator →
could be chance
Pharmacokinetics & dosing
HR 0.800.33–1.94
Cardiovascular events
HR 0.910.60–1.38
ThiazolidinedionesInsulinCardiovascular eventsPharmacokinetics & dosing
1 / 3

11 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 29581079